Sponsor

Angiochem Inc

Clinical research sponsor

Published trials6
Recruiting shown0
Roles1
SourceClinicalTrials.gov

Clinical trials

6 shown
ANG1005 in Leptomeningeal Disease From Breast CancerNCT03613181 · lead sponsor · 2023-12-01
UNKNOWN
ANG1005 in Breast Cancer Patients With Recurrent Brain MetastasesNCT02048059 · lead sponsor · 2014-04-01
COMPLETED
GRN1005 in Non-Small Cell Lung Cancer (NSCLC) Patients With Brain Metastases (GRABM-L)NCT01497665 · lead sponsor · 2011-11-01
TERMINATED
GRN1005 Alone or in Combination With Trastuzumab in Breast Cancer Patients With Brain MetastasesNCT01480583 · lead sponsor · 2011-10-01
COMPLETED
A Phase 1, Open-Label, Dose Escalation Study of ANG1005 in Patients With Advanced Solid Tumors and Metastatic Brain CancerNCT00539383 · lead sponsor · 2007-10-01
COMPLETED
Expanded Access to ANG1005 for Individual PatientsNCT02755987 · lead sponsor
NO_LONGER_AVAILABLE

Sponsor roles

lead sponsor6

How to interpret this record

CureCurrent links normalized diseases, medicines, registry study labels, sponsors and research sites. A link is not the same as a finding of clinical effectiveness. Our research guides explain how to compare studies, decode RxNorm identities, and avoid over-interpreting site and trial counts. See the published database coverage for mapping completeness.

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.